These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7097474)

  • 1. Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets.
    Aoyagi N; Ogata H; Kaniwa N; Ejima A
    J Pharmacobiodyn; 1982 Feb; 5(2):120-4. PubMed ID: 7097474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of microsize and ultramicrosize griseofulvin products in man.
    Straughn AB; Meyer MC; Raghow G; Rotenberg K
    J Pharmacokinet Biopharm; 1980 Aug; 8(4):347-62. PubMed ID: 7431226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of griseofulvin from tablets in humans and the correlation with its dissolution rate.
    Aoyagi N; Ogata H; Kaniwa N; Koibuchi M; Shibazaki T; Ejima A
    J Pharm Sci; 1982 Oct; 71(10):1165-9. PubMed ID: 7143217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bioavailability of griseofulvin PEG ultramicrosize (Gris-PEG) tablets in man under steady-state conditions.
    Barrett WE; Hanigan JJ
    Curr Ther Res Clin Exp; 1975 Sep; 18(3):491-500. PubMed ID: 810309
    [No Abstract]   [Full Text] [Related]  

  • 5. The bioavailability of ultramicrosize griseofulvin (Gris-PEG) tablets in man.
    Barrett WE; Bianchine JR
    Curr Ther Res Clin Exp; 1975 Sep; 18(3):501-9. PubMed ID: 810310
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioavailability of griseofulvin from tablets in beagle dogs and correlation with dissolution rate and bioavailability in humans.
    Aoyagi N; Ogata H; Kaniwa N; Koibuchi M; Shibazaki T; Ejima A; Tamaki N; Kamimura H; Katougi Y; Omi Y
    J Pharm Sci; 1982 Oct; 71(10):1169-72. PubMed ID: 7143218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative bioavailability of a microsize and ultramicrosize griseofulvin formulation in man.
    Lin C; Lim J; DiGiore C; Gural R; Symchowicz S
    J Int Med Res; 1982; 10(4):274-7. PubMed ID: 7117684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal absorption of griseofulvin from corn oil-in-water emulsions: effect of amount of corn oil ingested in man.
    Bates TR; Pieniaszek HJ; Sequeira JA; Rasmussen JE
    Arch Dermatol; 1977 Mar; 113(3):302-6. PubMed ID: 843096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human plasma and skin blister fluid levels of griseofulvin after its repeated administration.
    Schäfer-Korting M; Korting HC; Mutschler E
    Eur J Clin Pharmacol; 1985; 29(3):351-4. PubMed ID: 4076331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vitro liberation and the bioavailability of different brands of griseofulvin in plasma and urine in man.
    Terhaag B; Le Petit G; Pachaly C; Feller K
    Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):475-9. PubMed ID: 4055158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of griseofulvin from plain tablets in Göttingen minipigs and the correlation with bioavailability in humans.
    Aoyagi N; Ogata H; Kaniwa N; Ejima A; Yasuda Y; Tanioka Y
    J Pharmacobiodyn; 1984 Jan; 7(1):7-14. PubMed ID: 6726615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of griseofulvin plain tablets in stomach-emptying controlled rabbits and the correlation with bioavailability in humans.
    Aoyagi N; Ogata H; Kaniwa N; Ejima A
    J Pharmacobiodyn; 1984 Sep; 7(9):630-40. PubMed ID: 6527208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of different brands of griseofulvin tablets and its correlation to dissolution data.
    Khalafalla N; Elgholmy ZA; Khalil SA
    Pharmazie; 1980 Aug; 35(8):482-4. PubMed ID: 7433499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the high variable bioavailability of griseofulvin by SEDDS.
    Arida AI; Al-Tabakha MM; Hamoury HA
    Chem Pharm Bull (Tokyo); 2007 Dec; 55(12):1713-9. PubMed ID: 18057745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human plasma and skin blister fluid levels of griseofulvin following a single oral dose.
    Schäfer-Korting M; Korting HC; Mutschler E
    Eur J Clin Pharmacol; 1985; 29(1):109-13. PubMed ID: 4054199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of rabbits for GI drug absorption studies: relationship between dissolution rate and bioavailability of griseofulvin tablets.
    Maeda T; Takenaka H; Yamahira Y; Noguchi T
    J Pharm Sci; 1979 Oct; 68(10):1286-9. PubMed ID: 512862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bioavailability of griseofulvin from microsized and ultramicrosized tablets in nonfasting volunteers.
    Bijanzadeh M; Mahmoudian M; Salehian P; Khazainia T; Eshghi L; Khosravy A
    Indian J Physiol Pharmacol; 1990 Jul; 34(3):157-61. PubMed ID: 2286418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of griseofulvin from a novel capsule formulation.
    Fell JT; Calvert RT; Riley-Bentham P
    J Pharm Pharmacol; 1978 Aug; 30(8):479-82. PubMed ID: 28393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin.
    Ahmed IS; Aboul-Einien MH
    Eur J Pharm Sci; 2007 Sep; 32(1):58-68. PubMed ID: 17628451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Griseofulvin---phenobarbital interaction: a formulation-dependent phenomenon.
    Jamali F; Axelson JE
    J Pharm Sci; 1978 Apr; 67(4):466-70. PubMed ID: 641749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.